Pfizer Other Long-Term Assets 2010-2024 | PFE
Pfizer other long-term assets from 2010 to 2024. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Pfizer other long-term assets for the quarter ending September 30, 2024 were $10.486B, a 19.05% increase year-over-year.
- Pfizer other long-term assets for 2023 were $12.471B, a 5.26% decline from 2022.
- Pfizer other long-term assets for 2022 were $13.163B, a 71.42% increase from 2021.
- Pfizer other long-term assets for 2021 were $7.679B, a 57.39% increase from 2020.
Pfizer Annual Other Long-Term Assets
(Millions of US $) |
| 2023 |
$12,471 |
| 2022 |
$13,163 |
| 2021 |
$7,679 |
| 2020 |
$4,879 |
| 2019 |
$4,199 |
| 2018 |
$2,799 |
| 2017 |
$3,227 |
| 2016 |
$3,323 |
| 2015 |
$3,420 |
| 2014 |
$3,513 |
| 2013 |
$3,596 |
| 2012 |
$3,233 |
| 2011 |
$5,697 |
| 2010 |
$4,126 |
| 2009 |
$4,986 |
Pfizer Quarterly Other Long-Term Assets
(Millions of US $) |
| 2024-09-30 |
$10,486 |
| 2024-06-30 |
$10,710 |
| 2024-03-31 |
$11,197 |
| 2023-12-31 |
$12,471 |
| 2023-09-30 |
$8,808 |
| 2023-06-30 |
$13,028 |
| 2023-03-31 |
$12,965 |
| 2022-12-31 |
$13,163 |
| 2022-09-30 |
$10,890 |
| 2022-06-30 |
$7,659 |
| 2022-03-31 |
$7,879 |
| 2021-12-31 |
$7,679 |
| 2021-09-30 |
$6,705 |
| 2021-06-30 |
$6,056 |
| 2021-03-31 |
$4,744 |
| 2020-12-31 |
$4,879 |
| 2020-09-30 |
$4,355 |
| 2020-06-30 |
$4,327 |
| 2020-03-31 |
$4,166 |
| 2019-12-31 |
$4,199 |
| 2019-09-30 |
$4,920 |
| 2019-06-30 |
$4,388 |
| 2019-03-31 |
$4,333 |
| 2018-12-31 |
$2,799 |
| 2018-09-30 |
$2,980 |
| 2018-06-30 |
$2,896 |
| 2018-03-31 |
$2,896 |
| 2017-12-31 |
$3,227 |
| 2017-09-30 |
$3,388 |
| 2017-06-30 |
$3,466 |
| 2017-03-31 |
$3,329 |
| 2016-12-31 |
$3,323 |
| 2016-09-30 |
$4,759 |
| 2016-06-30 |
$4,618 |
| 2016-03-31 |
$4,003 |
| 2015-12-31 |
$3,420 |
| 2015-09-30 |
$3,911 |
| 2015-06-30 |
$3,635 |
| 2015-03-31 |
$3,716 |
| 2014-12-31 |
$3,513 |
| 2014-09-30 |
$3,421 |
| 2014-06-30 |
$3,574 |
| 2014-03-31 |
$3,759 |
| 2013-12-31 |
$3,596 |
| 2013-09-30 |
$4,982 |
| 2013-06-30 |
$5,143 |
| 2013-03-31 |
$5,432 |
| 2012-12-31 |
$3,233 |
| 2012-09-30 |
$5,862 |
| 2012-06-30 |
$5,806 |
| 2012-03-31 |
$5,943 |
| 2011-12-31 |
$5,697 |
| 2011-09-30 |
$5,205 |
| 2011-06-30 |
$4,761 |
| 2011-03-31 |
$4,718 |
| 2010-12-31 |
$4,126 |
| 2010-09-30 |
|
| 2010-06-30 |
$4,032 |
| 2010-03-31 |
$4,337 |
| 2009-12-31 |
$4,986 |
| 2009-09-30 |
$4,250 |
| 2009-06-30 |
$3,614 |
| 2009-03-31 |
$3,802 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$142.241B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
